GLP-1s aren't FDA-approved to treat rheumatoid arthritis, but many people notice improvement in their inflammation with the ...

Cassandra Smith has rheumatoid arthritis (RA) and knows all too well how debilitating the autoimmune condition can be. Her ...

A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

The analysis included 18,016 kidney transplant recipients with diabetes (2013 through 2020) covered by Medicare, of whom 10.9% had at least one GLP-1 RA prescription filled posttransplant.

A recently published ACC scientific statement highlighted major findings showing cardiovascular benefits from both semaglutide (GLP‑1 RA) and tirzepatide (GLP‑1/GIP RA)-including improvements ...

GLP-1 RA injectable use prevalence among adults with diabetes was 26.5% in 2024, but rates were higher in some age and racial groups.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects ...